Skip to main content
AmigoFish

Preparing For Commercial Launch In Oncology With Candel Therapeutics' Paul Peter Tak, M.D., Ph.D.

From Business Of Biotech · · 55 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

We love to hear from our listeners. Send us a message. (https://www.buzzsprout.com/1011661/fan_mail/new)

On this week's episode of the Business of Biotech, Paul Peter Tak, M.D., Ph.D., CEO at Candel Therapeutics, talks about the path from Phase 3 data to BLA submission for aglatimagene in localized prostate cancer and why “in situ immunization” could change how solid tumors are treated. He also talks through leadership and operating choices for minimizing risk in late-stage development, how FDA's Fast Track and RMAT designations aided communication and CMC planning, and how an outsourced commercial model can help companies prepare for launch and avoid premature fixed costs.

UPDATE (11/18/26): Candel Therapeutics recently became aware that the validation of the IU Assay will cause a six month delay in the completion of the BLA submission for aglatimagene, which is now expected mid-2027.

Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech (https://www.lifescienceleader.com/solution/the-business-of-biotech-podcast-lsl) tab at lifescienceleader.com.

Subscribe to our monthly Business of Biotech newsletter (https://www9.lifescienceleader.com/business-of-biotech-nl-sign-up/).

Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com

Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Back to Business Of Biotech · Report a problem